<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04727424</url>
  </required_header>
  <id_info>
    <org_study_id>TOGETHER_2</org_study_id>
    <nct_id>NCT04727424</nct_id>
  </id_info>
  <brief_title>Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms</brief_title>
  <official_title>A Multicenter, Prospective, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effect of Fluvoxamine, Ivermectin, Doxasozin and Interferon Lambda 1A in Mild COVID-19 and High Risk of Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardresearch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cytel Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fastgrants</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eiger BioPharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>RainWater Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardresearch</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in&#xD;
      certain subgroups of patients. To date, no treatment has been shown to be effective in&#xD;
      patients with early-onset disease and mild symptoms. Experimental studies have demonstrated a&#xD;
      potential anti-inflammatory role of Fluvoxamine, Metformin and Ivermectin in SARS-CoV-2&#xD;
      infections and observational studies have suggested a reduced complications in patients with&#xD;
      COVID-19 disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In December 2019 a series of viral pneumonia cases were reported in the city of Wuhan, China&#xD;
      and a new subtype of coronavirus has been identified as the causative agent of this&#xD;
      condition. On February 11, 2000 the disease has been characterized as COVID-19 and on March&#xD;
      11 the World Health Organization (WHO) declared a state of worldwide pandemic. On January 25,&#xD;
      2021 there are 98,794,942 cases and 2,124,193 documented deaths (global case-fatality ratio&#xD;
      of 2.15%).&#xD;
&#xD;
      To date, no early treatment has been identified as effective in combating this disease which&#xD;
      has been identified as with high morbidity and mortality. Epidemiological data suggest that&#xD;
      despite development of vaccines we will have hundreds od thousands of cases in the next two&#xD;
      years.&#xD;
&#xD;
      Thus, we propose the repositioning of three drugs which experimentally have shown&#xD;
      anti-inflammatory activity against SARS-CoV2 and some clinical evidence derived from&#xD;
      observational studies on reducing complications if used early on the disease, before&#xD;
      inflammatory cascade is fully activated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomly allocated to one of six treatment arms in a 1:1:1:1:1:1 ratio:&#xD;
Fluvoxamine&#xD;
Ivermectin&#xD;
Doxazosin&#xD;
Peginterferon Lambda&#xD;
Peginterferon Beta&#xD;
Placebo We will use a centralized random allocation schedule, generated by computer and stratified by site and age.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The investigational medical product will be packaged in similar bottles by a third party who will keep the allocation confidential until the end of the study. The bottles will be sealed and identified as &quot;Research Product with no commercial value&quot; and coded. They will be randomly allocated among the participants using a centralized randomization system The research subjects, medical assistance, administrative and health staff will not have access to the contents of the bottles. All arms will have a placebo counterpart with same dose schedule.&#xD;
All planned Data and Safety Monitoring Board (DSMB) interim analysis will be blinded. If needed a unblinded statistician will be provided if DSMB decides to stop any arm. At the end of the study, or early termination as per DMSB interim analysis plan, the arms will then be identified.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of fluvoxamine, ivermectin, doxasozin, peginterferon Lambda and peginterferon beta in changing the need for emergency care AND observation for more than 06 hours due to the worsening of COVID-19;</measure>
    <time_frame>28 days</time_frame>
    <description>Evaluation of emergency visits and observation unit stay &gt; 06 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of fluvoxamine, ivermectin, doxasozin, peginterferon lambda and peginterferon beta in changing need for Hospitalization due to COVID-19 progression and related complications, including lower respiratory tract infection (LRTI)</measure>
    <time_frame>28 days</time_frame>
    <description>Hospitalization due to COVID-19 progression and related complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in viral load on day 03 and 07 after randomization (first 400 enrolled participants on the IV arms)</measure>
    <time_frame>Day 3 and Day 7</time_frame>
    <description>Viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical changes (up to 28 days of randomization), defined as greater than 50% symptoms changing in reference to baseline symptoms)</measure>
    <time_frame>Randomization through day 28</time_frame>
    <description>time to &gt; 50% clinical symptoms changes as reported on baseline visit (self reported)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical failure, defined as time to need for hospitalization due to the clinical progression of COVID-19 or associated complications.</measure>
    <time_frame>Randomization through day 28</time_frame>
    <description>Time to hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with respiratory symptoms since randomization</measure>
    <time_frame>Randomization through day 28</time_frame>
    <description>Days with symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of all-cause hospitalizations</measure>
    <time_frame>Randomization through day 28</time_frame>
    <description>All cause hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of COVID-19 related hospitalizations</measure>
    <time_frame>Randomization through day 28</time_frame>
    <description>COVID-19 hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days on Mechanical Ventilator</measure>
    <time_frame>Randomization through day 28</time_frame>
    <description>Number of days on mechanical Ventilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days on Intensive Care Unit</measure>
    <time_frame>Randomization through day 28</time_frame>
    <description>Number of days on Intensive Care Unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days on hospitalizations</measure>
    <time_frame>Randomization through day 28</time_frame>
    <description>Number of days on Hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health and Functioning after COVID-19 disease</measure>
    <time_frame>Day 14 and Day 28</time_frame>
    <description>Self evaluation of health functioning post COVID using Promis Global Health Score. Short term scale is a 10 item patient-reported questionnaire using response options as a 5-point and one 11 point rating scale. Higher scores means better global health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO ordinal scale for clinical improvement</measure>
    <time_frame>Randomization through day 28</time_frame>
    <description>An 8 item Ordinal Scale for clinical status on COVID-19. Higher numbers means worse clinical status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number os days on respiratory Symptoms</measure>
    <time_frame>randomization through day 28</time_frame>
    <description>Number of days on respiratory symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence of Study drug</measure>
    <time_frame>Randomization through day 14</time_frame>
    <description>Percentage of adherence on Study drug</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">3645</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-Associated Coronavirus</condition>
  <arm_group>
    <arm_group_label>Fluvoxamine Maleate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluvoxamine 100 mg oral tablets:&#xD;
One tablet right after randomization (Day 0) followed by 100 mg BID for the following 09 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxasoxin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dosaxozin oral tablets (1 or 2 mg):&#xD;
One tablet right after randomization (Day 0) until Day 3, when uptritation of tablets will happen as per protocol, up to 4 pills daily (08 mg/ day) ending on Day 13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ivermectin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ivermectin 06 mg oral tablets:&#xD;
Tablets started right after randomization (Day 0; 400mcg/ kg dosing), administered once a day for 03 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo SC normal saline syringe (single day dosing schedule):&#xD;
Matching syringes containing 0,5 ml normal saline will be administered by SC route just after randomization Day 0 (single dose SC administration).&#xD;
OR&#xD;
Placebo oral tablets (3-day dosing schedule):&#xD;
Matching tablets started right after randomization using the dosing regimen of a medium 400mcg/ kg up to 90 kg weight, administered once a day for three consecutive days (including randomization day, which is designed as Day 0).&#xD;
OR&#xD;
Placebo oral tablets (10-day dosing schedule):&#xD;
Matching tablets started right after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)&#xD;
OR&#xD;
Placebo oral tablets (14-day dosing schedule):&#xD;
Matching tablets started right after randomization (Day 0) until Day 3, when uptritation of tablets will happen as per protocol, up to 4 pills daily (08 mg/ day) ending on Day 13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peginterferon Lambda</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peginterferon Lambda 180 mcg syringe:&#xD;
One syringe of Peginterferon Lambda will be administered by SC route just after randomization (Day 0 - single dose SC administration).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peginterferon Beta</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peginterferon Beta 125 mcg syringe:&#xD;
One syringe of Peginterferon Beta 1A will be administered by SC route just after randomization (Day 0 - single dose SC administration).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvoxamine Maleate 100 MG [Luvox]</intervention_name>
    <description>One tablet every 12 hours since randomization through day 09.</description>
    <arm_group_label>Fluvoxamine Maleate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxazosin 2 Mg Oral Tablet</intervention_name>
    <description>One to four tablets daily, as per uptritation schedule up to 08 mg/ day since randomization through day 13.</description>
    <arm_group_label>Doxasoxin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin 06 mg Oral Tablet</intervention_name>
    <description>Oral tablets administered once a day for three consecutive days (as of randomization day 0).</description>
    <arm_group_label>Ivermectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo SC normal saline syringe (single day dosing schedule):&#xD;
Matching syringes containing 0,5 ml normal saline will be administered by SC route just after randomization Day 0 (single dose SC administration).&#xD;
OR&#xD;
Placebo oral tablets (3-day dosing schedule):&#xD;
Matching tablets started right after randomization using the dosing regimen of a medium 400mcg/ kg up to 90 kg weight, administered once a day for three consecutive days (including randomization day, which is designed as Day 0).&#xD;
OR&#xD;
Placebo oral tablets (10-day dosing schedule):&#xD;
Matching tablets started right after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)&#xD;
OR&#xD;
Placebo oral tablets (14-day dosing schedule):&#xD;
Matching tablets started right after randomization (Day 0) until Day 3, when uptritation of tablets will happen as per protocol, up to 4 pills daily (08 mg/ day) ending on Day 13.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon Lambda-1a</intervention_name>
    <description>One syringe of 180 mcg of Peginterferon Lambda SC right after randomization Day 0 (single dose SC administration).</description>
    <arm_group_label>Peginterferon Lambda</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon Beta-1A Prefilled Syringe</intervention_name>
    <description>One syringe of 125 mcg of Peginterferon Beta SC right after randomization Day 0 (single dose SC administration).</description>
    <arm_group_label>Peginterferon Beta</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients over 18 years old with the ability to provide free and informed consent&#xD;
&#xD;
          2. Acute Flu-Like symptoms &lt; 07 days.&#xD;
&#xD;
          3. Patients with at least ONE enhancement criteria:&#xD;
&#xD;
               1. Age &gt; 50 years;&#xD;
&#xD;
               2. Diabetes mellitus requiring oral medication or insulin&#xD;
&#xD;
               3. Systemic arterial hypertension requiring at least 01 oral medication for BP&#xD;
                  control;&#xD;
&#xD;
               4. Known cardiovascular diseases (heart failure, congenital heart disease, valvar&#xD;
                  heart valve disease, coronary artery disease, cardiomyopathies)&#xD;
&#xD;
               5. Symptomatic lung disease (emphysema, chronic bronchitis)&#xD;
&#xD;
               6. Symptomatic asthma patients requiring chronic use of agents for control of&#xD;
                  symptoms.&#xD;
&#xD;
               7. Fever &gt; 38 C at baseline&#xD;
&#xD;
               8. Obesity, defined as BMI&gt; 30 kg / m2 body weight&#xD;
&#xD;
               9. Transplanted patients&#xD;
&#xD;
              10. Patient with stage IV chronic kidney disease or on dialysis.&#xD;
&#xD;
              11. Immunosuppressed patients/ using corticosteroid therapy (equivalent to maximum 10&#xD;
                  mg of prednisone per day) and/ or immunosuppressive therapy)&#xD;
&#xD;
              12. Patients with a history of cancer in the last 05 years or undergoing treatment of&#xD;
                  a current cancer&#xD;
&#xD;
              13. Chronic renal disease KDIGO IV or End-Stage Renal Disease on chronic ambulatory&#xD;
                  renal replacement therapy&#xD;
&#xD;
              14. Patients with important limitation of daily activities due to: Dyspnea, chest&#xD;
                  pain myalgia (limited to 25% of all randomizations)&#xD;
&#xD;
          4. Patient with positive rapid test for SARS-CoV2 antigen performed on occasion of the&#xD;
             screening or patient with a positive SARS-CoV2 diagnostic test within 07 days of the&#xD;
             onset of symptoms.&#xD;
&#xD;
          5. Willingness to use the proposed investigative treatment and follow the&#xD;
             protocol-related procedures foreseen in the research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Negative SARS-CoV2 test.&#xD;
&#xD;
          2. Flu-like symptom onset 08 days or more.&#xD;
&#xD;
          3. Patients with COVID-19 being referred for hospitalization;&#xD;
&#xD;
          4. &gt; 14 days of vaccination for SARS-CoV-2.&#xD;
&#xD;
          5. Patients with acute respiratory conditions due to other causes;&#xD;
&#xD;
          6. Dyspnea secondary to other acute and chronic respiratory causes or infections (eg:&#xD;
             Decompensated COPD, acute bronchitis, pneumonia, primary pulmonary arterial&#xD;
             hypertension)&#xD;
&#xD;
          7. Patients with clinical evidence of moderate disease and/or hospitalization indication&#xD;
&#xD;
          8. Patients using serotonin reception inhibitors (Donepezil, Sertraline)&#xD;
&#xD;
          9. Use of the following medications in the last 14 days:&#xD;
&#xD;
               1. Monoamine Oxide Inhibitors (MAOIs): Phenelzine, Tranylcypromine, Selegiline,&#xD;
                  Isocarboxazide, moclobemide;&#xD;
&#xD;
               2. Alpha-1 antagonists, Sotalol, Clonidine, Phosphodiesterase 5 inhibitors,&#xD;
                  Methyldopa, Prazosin, terasozin, Doxazosin).&#xD;
&#xD;
               3. Use of antiretroviral agents&#xD;
&#xD;
         10. Patients with severe psychiatric disorders or major uncontrolled depression or&#xD;
             controlled with any of the prohibited drugs (see above);&#xD;
&#xD;
         11. Pregnant or breastfeeding patients;&#xD;
&#xD;
         12. History of severe ventricular cardiac arrhythmia (ventricular tachycardia, patients&#xD;
             with ventricular fibrillation recovered) or Long QT Syndrome;&#xD;
&#xD;
         13. Known history of symptomatic orothosthatic hypotension, syncope, postural orthostatic&#xD;
             tachycardia syndrome (POTS), Neurally-mediated syncope on the last 12 months, less&#xD;
             than 12 weeks of cerebrovascular accident, myocardial infarction, cardiovascular&#xD;
             intervention, moderate to severe mitral or aortic stenosis.&#xD;
&#xD;
         14. Surgical procedure designed to occur during treatment or up to 04 days after the last&#xD;
             dose of the study medication;&#xD;
&#xD;
         15. Current daily and / or uncontrolled alcoholism;&#xD;
&#xD;
         16. History of seizures in the last month or uncontrolled medical condition;&#xD;
&#xD;
         17. Clinical history of Liver Cirrhosis or Child-Pugh C classification;&#xD;
&#xD;
         18. Patients with known severe degenerative neurological diseases and / or diseases&#xD;
             serious mental disorders;&#xD;
&#xD;
         19. Inability of the patient or representative to give consent or adhere to the procedures&#xD;
             proposed in the protocol;&#xD;
&#xD;
         20. Known hypersensitivity and / or intolerance to Fluvoxamine, Ivermectin or Metformin;&#xD;
&#xD;
         21. Inability to take oral medications;&#xD;
&#xD;
         22. Inability to follow protocol-related procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Gender will be assumed as patient self-reported</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilmar Reis, MD,PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Cardresearch - Cardiologia Assistencial e de Pesquisa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward J Mills, FRCP</last_name>
    <role>Study Director</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilmar Reis, MD, PhD</last_name>
    <phone>+553132416574</phone>
    <email>administrador@cardresearch.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eduardo Santos, MD, PhD</last_name>
    <phone>+553132416574</phone>
    <email>duduaugusto1@yahoo.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Betim</name>
      <address>
        <city>Betim</city>
        <state>MG</state>
        <zip>32550770</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela C Medeiros, MD,PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Tainara S Vieira</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital e Maternidade Santa Rita</name>
      <address>
        <city>Contagem</city>
        <state>MG</state>
        <zip>32215000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thiago S Ferreira, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Governador Valadares</name>
      <address>
        <city>Governador Valadares</city>
        <state>MG</state>
        <zip>35010-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adhemar DF Neto, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Marina L Marques, SC</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>City of Ibirité</name>
      <address>
        <city>Ibirité</city>
        <state>MG</state>
        <zip>30240528</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aline Milagres, RN</last_name>
    </contact>
    <contact_backup>
      <last_name>Carla Silva, SC</last_name>
      <email>hsfapesq@cardresearch.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>City of Nova Lima</name>
      <address>
        <city>Nova Lima</city>
        <state>MG</state>
        <zip>34000000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leticia F Costa, RN</last_name>
    </contact>
    <contact_backup>
      <last_name>Rosemary M Silva</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>City of Santa Luzia</name>
      <address>
        <city>Santa Luzia</city>
        <state>MG</state>
        <zip>33105160</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Augusto SM Silva, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Vitoria HS Campos, SC</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>City of Sete Lagoas</name>
      <address>
        <city>Sete Lagoas</city>
        <state>MG</state>
        <zip>35700-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinicius A Correa, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Castilho Vitor Quirino, SC</last_name>
      <email>vitor-quirino@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CARDRESEARCH - Cardiologia Assistencial e de Pesquisa</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30150240</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Izabel Silva, SC</last_name>
      <phone>553132416574</phone>
      <email>coordpesq@cardresearch.org</email>
    </contact>
    <investigator>
      <last_name>Gilmar Reis, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Brumadinho</name>
      <address>
        <city>Brumadinho</city>
        <state>Minas Gerais</state>
        <zip>35.460-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo D Calegari, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eduardo Calegari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Universitário FIPMOC</name>
      <address>
        <city>Montes Claros</city>
        <state>Minas Gerais</state>
        <zip>39.408-007</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Maria, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ana Maria R Nogueira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Paula FG Alvarenga, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Ouro Preto</name>
      <address>
        <city>Ouro Preto</city>
        <state>Minas Gerais</state>
        <zip>35400000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonardo CM Savassi, MD, PhD</last_name>
      <email>leosavassi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Leonardo Savassi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Randomized study</keyword>
  <keyword>Fluvoxamine</keyword>
  <keyword>Ivermectin</keyword>
  <keyword>Doxasozin</keyword>
  <keyword>Peginterferon Lambda</keyword>
  <keyword>Peginterferon Beta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Doxazosin</mesh_term>
    <mesh_term>Fluvoxamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient tables and main data.</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>As of protocol termination</ipd_time_frame>
    <ipd_access_criteria>Upon request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

